Dayvigo (lemborexant) is a small molecule pharmaceutical. Lemborexant was first approved as Dayvigo on 2020-04-07. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against orexin receptor type 2 and orexin receptor type 1. Dayvigo's patent is valid until 2035-10-21 (FDA).
|Indication||sleep initiation and maintenance disorders|
|Drug Class||Orexin antagonist|